News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
203,416 Results
Type
Article (20623)
Company Profile (23)
Press Release (182768)
Multimedia
Podcasts (40)
Webinars (2)
Section
Business (29887)
Career Advice (696)
Deals (5486)
Drug Delivery (62)
Drug Development (23877)
Employer Resources (47)
FDA (5093)
Job Trends (4294)
News (57287)
Policy (8690)
Tag
2027 Bio NC Standard (1)
2027 Biotech Bay Standard (1)
2027 Genetown Standard (2)
2027 Pharm Country Digital (1)
2027 Pharm Country Premier (1)
2027 Pharm Country Standard (2)
40 Under 40 (1)
Academia (1256)
Accelerated approval (31)
ADA (9)
Adcomms (24)
Allergies (130)
Alliances (13409)
ALS (80)
Alzheimer's disease (1134)
Antibody-drug conjugate (ADC) (217)
Approvals (6675)
Artificial intelligence (233)
ASCO (100)
Autoimmune disease (132)
Automation (16)
Bankruptcy (85)
Belgium (3)
Best Places to Work (4266)
BIO (16)
Biologics (13)
BIOSECURE Act (8)
Biosimilars (138)
BioSpace Insights (32)
Biotechnology (21)
Bispecific (2)
Bladder cancer (98)
Brain cancer (44)
Breast cancer (276)
Cancer (2384)
Cardiovascular disease (230)
Career advice (690)
Career pathing (24)
CAR-T (132)
CDC (48)
CDMO (73)
Celiac Disease (1)
Cell-line development (1)
Cell therapy (366)
Cervical cancer (20)
Clinical research (29883)
Collaboration (749)
Commercialization (11)
Company closure (3)
Compensation (194)
Complete response letters (40)
COVID-19 (2300)
CRISPR (50)
C-suite (299)
Cystic fibrosis (66)
Data (4073)
Decentralized trials (2)
Denatured (5)
Depression (63)
Dermatology (88)
Diabetes (296)
Diagnostics (1866)
Digital health (18)
Diversity (6)
Diversity, equity & inclusion (24)
Drug discovery (148)
Drug pricing (110)
Drug shortages (18)
Duchenne muscular dystrophy (222)
Earnings (19145)
Editorial (43)
Employer branding (6)
Employer resources (59)
Events (24854)
Executive appointments (240)
Eye disease (6)
FDA (8282)
Fibrodysplasia Ossificans Progressiva (8)
Fragile X (1)
Friedreich's ataxia (14)
Frontotemporal dementia (21)
Funding (644)
Gene editing (94)
Generative AI (27)
Gene therapy (403)
GLP-1 (488)
Government (2585)
Grass and pollen (5)
Guidances (180)
Healthcare (5942)
Hematology (73)
HIV (56)
Huntington's disease (34)
Idiopathic pulmonary fibrosis (1)
IgA nephropathy (65)
Immunology and inflammation (139)
Immuno-oncology (42)
Indications (121)
Infectious disease (2610)
Inflammatory bowel disease (64)
Inflation Reduction Act (7)
Influenza (121)
Intellectual property (88)
Interviews (155)
IPO (3610)
IRA (31)
Job creations (730)
Job search strategy (566)
JPM (29)
Kidney cancer (11)
Kidney disease (46)
Labor market (30)
Layoffs (159)
Leadership (23)
Legal (5179)
Licensing (24)
Liver cancer (37)
Longevity (44)
Lung cancer (316)
Lung diease (4)
Lymphoma (188)
Machine learning (16)
Management (20)
Manufacturing (332)
Marketing (10)
MASH (37)
Medical device (2814)
Medtech (2865)
Mergers & acquisitions (4722)
Metabolic disorders (687)
mRNA (168)
Multiple sclerosis (106)
Multispecific (1)
NASH (4)
Netherlands (7)
Neurodegenerative disease (219)
Neuropsychiatric disorders (44)
Neuroscience (1828)
Neurotech (1)
NextGen: Class of 2026 (1929)
Non-profit (1810)
Now hiring (7)
Obesity (322)
Opinion (160)
Ovarian cancer (85)
Pain (79)
Pancreatic cancer (135)
Parkinson's disease (175)
Partnered (11)
Patents (216)
Patient recruitment (305)
Patient selection (17)
Peanut (52)
People (11507)
Peptides (6)
Pharmaceutical (6)
Pharmacy benefit managers (12)
Phase 1 (8825)
Phase 2 (12725)
Phase 3 (10939)
Pipeline (4830)
Policy (168)
Postmarket research (1256)
Preclinical (3943)
Press Release (15)
Prostate cancer (106)
Psychedelics (40)
Radioligand (1)
Radiopharmaceuticals (125)
Rare diseases (691)
Real estate (931)
Recruiting (23)
Regenerative medicine (4)
Regulatory (9890)
Reports (26)
Research institute (1059)
Resumes & cover letters (131)
Rett syndrome (39)
RNA editing (6)
RSV (92)
Schizophrenia (63)
Series A (90)
Series B (64)
Service/supplier (1)
Sickle cell disease (61)
Special edition (9)
Spinal muscular atrophy (129)
Sponsored (17)
Startups (911)
Stem cells (1)
Stomach cancer (10)
Substance use disorders (7)
Supply chain (38)
Tariffs (38)
The Weekly (47)
Vaccines (1079)
Venture capital (44)
Weight loss (238)
Wet AMD (5)
Women's health (58)
Worklife (10)
Date
Last 7 days (142)
Last 30 days (771)
Last 365 days (9174)
2026 (4566)
2025 (6168)
2024 (11051)
2023 (7231)
2022 (17918)
2021 (19385)
2020 (17469)
2019 (13629)
2018 (10196)
2017 (5766)
2016 (9072)
2015 (10290)
2014 (7239)
2013 (5676)
2012 (5761)
2011 (6197)
2010 (3553)
Location
Africa (325)
Alabama (18)
Alaska (1)
Arizona (82)
Arkansas (2)
Asia (12383)
Australia (2506)
California (4286)
Canada (1123)
China (555)
Colorado (156)
Connecticut (198)
Delaware (149)
Europe (35835)
Florida (734)
Georgia (155)
Hawaii (3)
Idaho (11)
Illinois (358)
India (46)
Indiana (331)
Iowa (5)
Japan (300)
Kansas (56)
Kentucky (19)
Louisiana (19)
Maine (31)
Maryland (600)
Massachusetts (3098)
Michigan (79)
Minnesota (144)
Mississippi (1)
Missouri (60)
Montana (8)
Nebraska (5)
Nevada (46)
New Hampshire (17)
New Jersey (1512)
New Mexico (8)
New York (1285)
North Carolina (495)
North Dakota (2)
Northern California (2244)
Ohio (84)
Oklahoma (3)
Oregon (5)
Pennsylvania (977)
Puerto Rico (3)
Rhode Island (13)
South America (354)
South Carolina (15)
South Dakota (1)
Southern California (1628)
Tennessee (65)
Texas (501)
United States (15604)
Utah (101)
Vermont (1)
Virginia (61)
Washington D.C. (27)
Washington State (358)
Wisconsin (29)
Wyoming (2)
203,416 Results for "itm isotopen technologien muenchen ag".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Mergers & acquisitions
Telix buys ITM for $1.65B in ‘supercritical’ radiopharma M&A
Aside from its manufacturing and distribution footprint, ITM Isotope Technologies Munich will give Telix Pharmaceuticals the late-stage ITM-11, being developed for gastroenteropancreatic neuroendocrine tumors. The asset was rejected by the FDA last month for manufacturing concerns.
September 21, 2026
·
3 min read
·
Tristan Manalac
Manufacturing
FDA rejects ITM Isotope’s radiopharma therapy over manufacturing issues
ITM Isotope Technologies plans on resubmitting its advanced cancer radiopharma therapy to the FDA after addressing the agency’s concerns.
August 11, 2026
·
1 min read
·
Gabrielle Masson
Press Releases
ITM and Lumara Bio to Announce New Data for ¹⁷⁷Lu-edotreotide (ITM-11) and Ga-DPI-4452 at EANM 2026
October 7, 2026
·
5 min read
Press Releases
ITM Receives Complete Response Letter for ¹⁷⁷Lu-edotreotide (ITM-11)
August 10, 2026
·
3 min read
Press Releases
ITM and Lumara Bio Announce Real-World Re-treatment Data and Dosimetry Results from COMPETE for ¹⁷⁷Luedotreotide (ITM-11) in GEP-NETs at ASTRO 2026
September 28, 2026
·
4 min read
Press Releases
Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse
September 21, 2026
·
14 min read
Press Releases
ITM and Lumara Bio Announce Upcoming Dosimetry and Re-treatment Data Presentations on ¹⁷⁷Lu-edotreotide at ASTRO 2026
September 23, 2026
·
3 min read
Press Releases
ITM Introduces Lumara Bio as Its New Oncology Therapeutics Division
July 27, 2026
·
3 min read
Press Releases
ITM, Helmholtz Munich and the University of Münster Announce Updated Preliminary Phase 1 Data with ITM-31 in Glioblastoma Patients
June 29, 2026
·
6 min read
Press Releases
ITM Announces Primary Results from the Phase 3 COMPETE Trial Published in The Lancet Comparing ¹⁷⁷Lu-edotreotide (ITM-11) vs. Everolimus in Advanced GEP-NETs
July 7, 2026
·
5 min read
1 of 20,342
Next
